Evolving First-Line Treatment Strategies for uHCC.

Opinion
Video

James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma (uHCC) based on NCCN Guidelines, and discusses the evolving treatment landscape, including the rationale for combination immunotherapy (IO) and how additional IO combinations may address unmet needs like depth of response and resistance.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      Give a high-level overview of systemic therapy for untreated uHCC

      Briefly dDiscuss the evolving treatment landscape of systemic therapy in untreated uHCC.

      • What has been the rationale for combination immunotherapy (IO) in this setting?
      • What are current unmet needs, and how could additional IO combinations address them?
      • E.g,. depth of response, resistance,…
      Related Content